Skip to Content

Posts tagged with "Drug Prices"

  • Clinical Trials

    Cost of Trials

    There’s been an interesting discussion about pharma R&D productivity and drug pricing on Twitter the last few days – here’s the starting point, from John Tucker. His thesis is that the hefty rate of inflation for medical services/hospitalization, where the data seem alarmingly solid, is one of the things driving the problem. T… Read More
  • Business and Markets

    Drug Synthesis In Printed Reactors

    I’m still trying to get my bearings with this new paper from the Cronin group at Glasgow. What it proposes is a new style of API (active pharmaceutical ingredient) production. Instead of being done in bench- or process-scale lab glassware or in production-plant reactors, these syntheses take place in 3D-printed reactors, connected together in… Read More
  • Business and Markets

    Hospitals Making Drugs?

    This story from the New York Times got a lot of attention yesterday, and understandably so. It’s fundamentally about the shortage of some generic drugs, a problem that’s been with us for some years now in one form or another. My own belief is that much of this is a regulatory problem, and I note… Read More
  • Drug Development

    Drug Development Costs Revisited

    A recent paper on drug development costs did not impress me. But if possible, it impressed Matthew Herper at Forbes even less. That’s the one where the authors looked at a number of companies that had been around long enough to develop one drug – they figured that this would give a cleaner read on… Read More
  • Business and Markets

    It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a response to the Tufts estimates on these costs, and I’m not going to help much, because I have some things to debate about this paper myself. The authors… Read More
  • Business and Markets

    Mylan Begins Harvesting the Crop It’s Sown

    There’s an interesting fight going on inside Mylan Pharmaceuticals. They, of course, are the longtime generic drug maker whose EpiPen prices have (understandably) made them a lightning rod for complaints about drug pricing in general. This New York Times article will give you the flavor of the company, and most unappetizing it is: To understa… Read More
  • Drug Prices

    Fixing the Generic Drug Process

    It’s very early in Scott Gottlieb’s tenure at the FDA, but I like what he has to say about generic drug approvals. Several times here, I’ve gone on about how a lot of the terrible pricing situations we’re seeing in generics are due to gaming of the regulatory system, and how the FDA could do… Read More
  • Alzheimer's Disease

    There Are Failures, You Know

    This exact point came up around here when we last discussed FDA reform, so it’s good to see it made at length in the New England Journal of Medicine. Remember solanezumab? That was the amyloid-targeting antibody that Eli Lilly kept on investigating in trial after trial, looking for some effect on Alzheimer’s. Last November, the final… Read More
  • Business and Markets

    Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old generic steroid to the US market. They did no new registrational studies in the clinic, in case you’re wondering. There was a drug-drug interaction study, ADME work, that sort of thing… Read More
  • Drug Prices

    The Case of Marathon Pharmaceuticals

    So since drug pricing and FDA regulations are so much in the news, it would seem like the perfect time for a small company to game the system for big profits, right? That’s apparently what Marathon Pharmaceuticals believes. They just got approval for deflazacort, a steroid, as a treatment for Duchenne Muscular Dystrophy. Duchenne is… Read More
123...